Literature DB >> 24865794

Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations.

Jennifer S Gewandter1, Robert H Dworkin, Dennis C Turk, Michael P McDermott, Ralf Baron, Marc R Gastonguay, Ian Gilron, Nathaniel P Katz, Cyrus Mehta, Srinivasa N Raja, Stephen Senn, Charles Taylor, Penney Cowan, Paul Desjardins, Rozalina Dimitrova, Raymond Dionne, John T Farrar, David J Hewitt, Smriti Iyengar, Gary W Jay, Eija Kalso, Robert D Kerns, Richard Leff, Michael Leong, Karin L Petersen, Bernard M Ravina, Christine Rauschkolb, Andrew S C Rice, Michael C Rowbotham, Cristina Sampaio, Sren H Sindrup, Joseph W Stauffer, Ilona Steigerwald, Jonathan Stewart, Jeffrey Tobias, Rolf-Detlef Treede, Mark Wallace, Richard E White.   

Abstract

Proof-of-concept (POC) clinical trials play an important role in developing novel treatments and determining whether existing treatments may be efficacious in broader populations of patients. The goal of most POC trials is to determine whether a treatment is likely to be efficacious for a given indication and thus whether it is worth investing the financial resources and participant exposure necessary for a confirmatory trial of that intervention. A challenge in designing POC trials is obtaining sufficient information to make this important go/no-go decision in a cost-effective manner. An IMMPACT consensus meeting was convened to discuss design considerations for POC trials in analgesia, with a focus on maximizing power with limited resources and participants. We present general design aspects to consider including patient population, active comparators and placebos, study power, pharmacokinetic-pharmacodynamic relationships, and minimization of missing data. Efficiency of single-dose studies for treatments with rapid onset is discussed. The trade-off between parallel-group and crossover designs with respect to overall sample sizes, trial duration, and applicability is summarized. The advantages and disadvantages of more recent trial designs, including N-of-1 designs, enriched designs, adaptive designs, and sequential parallel comparison designs, are summarized, and recommendations for consideration are provided. More attention to identifying efficient yet powerful designs for POC clinical trials of chronic pain treatments may increase the percentage of truly efficacious pain treatments that are advanced to confirmatory trials while decreasing the percentage of ineffective treatments that continue to be evaluated rather than abandoned.
Copyright © 2014 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical trials; IMMPACT; Methodology; Proof of concept

Mesh:

Year:  2014        PMID: 24865794      PMCID: PMC4500524          DOI: 10.1016/j.pain.2014.05.025

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  33 in total

1.  Reducing Truancy and Fostering a Willingness to Attend School: Results from a Randomized Trial of a Police-School Partnership Program.

Authors:  Lorraine Mazerolle; Emma Antrobus; Sarah Bennett; Elizabeth Eggins
Journal:  Prev Sci       Date:  2017-05

2.  What Do We Owe Patients with Chronic Pain?

Authors:  Mark D Sullivan
Journal:  Pain Med       Date:  2019-05-01       Impact factor: 3.750

Review 3.  CB2 Cannabinoid receptors as a therapeutic target-what does the future hold?

Authors:  Amey Dhopeshwarkar; Ken Mackie
Journal:  Mol Pharmacol       Date:  2014-08-08       Impact factor: 4.436

Review 4.  Improving Study Conduct and Data Quality in Clinical Trials of Chronic Pain Treatments: IMMPACT Recommendations.

Authors:  Jennifer S Gewandter; Robert H Dworkin; Dennis C Turk; Eric G Devine; David Hewitt; Mark P Jensen; Nathaniel P Katz; Amy A Kirkwood; Richard Malamut; John D Markman; Bernard Vrijens; Laurie Burke; James N Campbell; Daniel B Carr; Philip G Conaghan; Penney Cowan; Mittie K Doyle; Robert R Edwards; Scott R Evans; John T Farrar; Roy Freeman; Ian Gilron; Dean Juge; Robert D Kerns; Ernest A Kopecky; Michael P McDermott; Gwendolyn Niebler; Kushang V Patel; Richard Rauck; Andrew S C Rice; Michael Rowbotham; Nelson E Sessler; Lee S Simon; Neil Singla; Vladimir Skljarevski; Tina Tockarshewsky; Geertrui F Vanhove; Ajay D Wasan; James Witter
Journal:  J Pain       Date:  2019-12-13       Impact factor: 5.820

Review 5.  Essential statistical principles of clinical trials of pain treatments.

Authors:  Robert H Dworkin; Scott R Evans; Omar Mbowe; Michael P McDermott
Journal:  Pain Rep       Date:  2020-12-18

Review 6.  Design and conduct of confirmatory chronic pain clinical trials.

Authors:  Nathaniel Katz
Journal:  Pain Rep       Date:  2020-12-18

Review 7.  Neuropathic pain.

Authors:  Luana Colloca; Taylor Ludman; Didier Bouhassira; Ralf Baron; Anthony H Dickenson; David Yarnitsky; Roy Freeman; Andrea Truini; Nadine Attal; Nanna B Finnerup; Christopher Eccleston; Eija Kalso; David L Bennett; Robert H Dworkin; Srinivasa N Raja
Journal:  Nat Rev Dis Primers       Date:  2017-02-16       Impact factor: 52.329

Review 8.  Hydrocodone Bitartrate ER (Hysingla® ER): A Review in Chronic Pain.

Authors:  Sohita Dhillon
Journal:  Clin Drug Investig       Date:  2016-11       Impact factor: 2.859

9.  Response to Crevenna and Ashbury, Vallance and Bolam, and Crevenna and Keilani regarding the effects of exercise on chemotherapy-induced peripheral neuropathy.

Authors:  Ian R Kleckner; Charles Kamen; Jennifer S Gewandter; Nimish A Mohile; Charles E Heckler; Eva Culakova; Chunkit Fung; Michelle C Janelsins; Matthew Asare; Po-Ju Lin; Pavan S Reddy; Jeffrey Giguere; Jeffrey Berenberg; Shelli R Kesler; Karen M Mustian
Journal:  Support Care Cancer       Date:  2018-10-29       Impact factor: 3.603

10.  COMT Genotype and Efficacy of Propranolol for TMD Pain: A Randomized Trial.

Authors:  G D Slade; R B Fillingim; R Ohrbach; H Hadgraft; J Willis; S J Arbes; I E Tchivileva
Journal:  J Dent Res       Date:  2020-10-08       Impact factor: 6.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.